Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Recruiting
Astex Pharmaceuticals
Phase 1/Phase 2
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660,
determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended
dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target
engagement data, in subjects with advanced solid tumors or lymphoma for whom standard
life-prolonging measures are not available.
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Recruiting
Astex Pharmaceuticals, Inc.
Phase 1/Phase 2
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660,
determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended
dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target
engagement data, in subjects with advanced solid tumors or lymphoma for whom standard
life-prolonging measures are not available.
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Recruiting
Astex Pharmaceuticals, Inc.
Phase 1
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and
in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid
leukemia (AML). The duration of the study is expected to be approximately 30 months.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
